US 11,931,513 B2
Patient interface
Rupert Christian Scheiner, Sydney (AU); William Laurence Hitchcock, Sydney (AU); Anthony Paul Barbara, Sydney (AU); Adam Francis Barlow, Sydney (AU); Craig David Edwards, Sydney (AU); Lachlan Richard Goldspink, Sydney (AU); Kirrily Michele Haskard, Sydney (AU); Murray William Lee, Sydney (AU); Frederick Arlet May, Sydney (AU); Gerard Michael Rummery, Woodford (AU); Shiva Kumar Shanmuga Sundara, Sydney (AU); Chia Ik Tan, Sydney (AU); Stewart Joseph Wagner, Hawkesbury (AU); Alicia Kristianne Wells, Sydney (AU); Martin Forrester, Trenton (CA); and Ralph Jourdan, Morfelden (DE)
Assigned to ResMed Pty Ltd, Bella Vista (AU)
Filed by ResMed Pty Ltd, Bella Vista (AU)
Filed on Dec. 19, 2022, as Appl. No. 18/083,707.
Application 18/083,707 is a continuation of application No. 16/710,216, filed on Dec. 11, 2019, granted, now 11,612,711.
Application 16/710,216 is a continuation of application No. 14/760,808, granted, now 10,543,332, issued on Jan. 28, 2020, previously published as PCT/AU2014/000026, filed on Jan. 16, 2014.
Claims priority of provisional application 61/904,974, filed on Nov. 15, 2013.
Claims priority of provisional application 61/839,916, filed on Jun. 27, 2013.
Claims priority of provisional application 61/837,521, filed on Jun. 20, 2013.
Claims priority of provisional application 61/823,353, filed on May 14, 2013.
Claims priority of provisional application 61/823,192, filed on May 14, 2013.
Claims priority of provisional application 61/817,674, filed on Apr. 30, 2013.
Claims priority of application No. 2013900132 (AU), filed on Jan. 16, 2013; application No. 605907 (NZ), filed on Jan. 16, 2013; and application No. 2013900168 (AU), filed on Jan. 18, 2013.
Prior Publication US 2023/0149651 A1, May 18, 2023
Int. Cl. A61M 16/06 (2006.01); A61M 16/00 (2006.01); A61M 16/08 (2006.01); A61M 16/10 (2006.01); A61M 16/16 (2006.01)
CPC A61M 16/0622 (2014.02) [A61M 16/0069 (2014.02); A61M 16/06 (2013.01); A61M 16/0672 (2014.02); A61M 16/0683 (2013.01); A61M 16/0875 (2013.01); A61M 16/10 (2013.01); A61M 2016/0027 (2013.01); A61M 2016/0039 (2013.01); A61M 16/1055 (2013.01); A61M 16/107 (2014.02); A61M 16/16 (2013.01); A61M 2202/0208 (2013.01); A61M 2205/0216 (2013.01); A61M 2210/0618 (2013.01)] 29 Claims
OG exemplary drawing
 
1. A patient interface configured for sealed delivery of a supply of pressurized, breathable gas at a continuously positive pressure with respect to ambient air pressure to a patient's nares, the patient interface being configured to maintain a therapeutic pressure in a range of about 4 cmH2O to about 30 cmH2O above ambient air pressure in use, throughout the patient's respiratory cycle, while the patient is sleeping, to ameliorate sleep disordered breathing, the patient interface comprising:
a frame;
a seal-forming structure connected to the frame and the seal-forming structure including an opening formed in the seal-forming structure and configured to deliver the supply of pressurized, breathable gas to the patient's airway, the seal-forming structure including:
a first region positioned proximal to the opening on each lateral side of the opening, the first region being configured to contact the patient's nose;
a second region positioned adjacent to and laterally outward of each first region, the second region being thicker than the adjacent first region; and
a third region positioned adjacent to and laterally outward of each second region, the third region having a different thickness relative to the adjacent second region;
wherein the seal-forming structure has a curved shape from each first region, through the adjacent second region, and to the adjacent third region, an apex of each curved shape being located in each second region;
a gas washout vent including at least one vent hole and being configured to allow a flow of patient exhaled CO2 to be discharged to ambient from the patient interface; and
a positioning and stabilising structure that includes a strap and is connected to the frame, the positioning and stabilising structure being configured to maintain the seal-forming structure in sealing contact with patient's face while maintaining the therapeutic pressure at the patient's nares,
wherein a first portion of the seal-forming structure is configured to be positioned proximal to the patient's upper lip in use, a second portion of the seal-forming structure is positioned opposite the first portion across the opening, and the second portion of the seal-forming structure is configured to contact the underside of the patient's nose proximal to the pronasale in use.